Article Text

Download PDFPDF
125 A novel protein target to reduce plaque formation and lipid deposition in experimental atherosclerosis
  1. Pola Verschoor1,
  2. Megan Fraser2,
  3. Mirela Delibegovic2,
  4. Graeme F Nixon2,
  5. Justin J Rochford3
  1. 1Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, UK
  2. 2University of Aberdeen
  3. 3Rowett Institute, University of Aberdeen

Abstract

Atherosclerotic plaque formation is the result of lipid accumulation in the arterial intima leading to foam cell formation and is exacerbated by high fat diet feeding. The accumulation of lipids in arterial plaques can be viewed as a problem of lipid storage, i.e. adipose depots are not able to efficiently buffer the excessive lipid intake. Insufficient storage capacity can lead to lipid overflow into other organs, particularly the liver, resulting in a cholesterol imbalance. Fatty liver subsequently results in increased plasma lipids which underlie lipid plaque formation. We have recently demonstrated that a protein previously uncharacterized in the cardiovascular system, protein enriched in astrocytes (PEA)−15, plays a central role in maintaining normal arterial function, particularly in response to stress stimuli. Specifically, PEA-15 prevents proliferation by acting as a brake on extracellular signal-regulated kinases (ERK) 1/2-dependent gene expression. ERK1/2 activity is a critical component in adipose tissue expansion. In the current study we hypothesised that PEA-15 can regulate adipose tissue expansion which could ultimately control lipid plaque formation in atherosclerosis. We generated a double knockout (KO) transgenic mouse line null for both PEA-15 and apolipoprotein E (ApoE). Mice were fed a high fat/cholesterol diet (HFD) (42% kcal from fat) for 16 weeks to induce plaque formation. After 16 weeks of HFD, the PEA-15/ApoE KO mice weighed significantly more than ApoE KO mice (PEA-15/ApoE KO – 44.1±1.7 g versus ApoE KO – 38.4±1.3 g, p<0.05, n=6). This was the result of increased white adipose tissue depots in PEA-15/ApoE KO mice. Surprisingly, despite this increased adipose tissue weight, total plaque area in the thoracic aorta was significant decreased in PEA-15/ApoE KO mice (as measured by contrast microscopy 17.8±2.2% versus 27.6±3.3% in ApoE KO, p<0.05, n=6). Abdominal adipose tissue was examined in these mice. While adipocytes were similar in number compared to ApoE KO, adipocytes in PEA-15/ApoE KO mice were significant larger (5.7±0.5 µm2 compared to 4.2±0.5 µm2 in ApoE KO, p<0.05, n=7). This suggests that PEA-15 plays a role in lipid storage capacity in adipocytes. To determine if this is a protective mechanism against lipid absorption in other important peripheral metabolic tissues, such as the liver, we examined hepatic lipid levels. Hepatic triglyceride levels were significantly decreased in PEA-15/ApoE KO mice (72.7±10.2 µg/mg liver versus 114.9±11.1 µg/mg liver in ApoE, p<0.05, n=5–7). In conclusion, this study demonstrates that PEA-15 protein deletion attenuates atherosclerotic plaque formation. This coincides with efficient lipid storage capacity of adipocytes, thereby protecting other metabolic organs from the associated increased lipid burden. Therefore, decreasing PEA-15 levels and/or activity may be a therapeutic target to alter the progression of atherosclerosis.

  • Atherosclerosis
  • plaques
  • lipids

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.